Evidence map›Paper›PMID 30464682›Full record

SynthesisCurrent oncology (Toronto, Ont.)2018

Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.

M Carrier, N Blais, M Crowther, P Kavan, G Le Gal, O Moodley, S Shivakumar, V Tagalakis, C Wu, A Y Y Lee

Open access · goldAbstract readSystematic ReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Current oncology (Toronto, Ont.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Treatment and secondary prophylaxis of venous thromboembolism in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  8. Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Review
  9. Review
  10. Article
  11. Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Review
  12. Article
  13. Review
  14. Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives.TH open : companion journal to thrombosis and haemostasis · 2021
    Article
  15. Review
  16. Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Observational
  17. Review
  18. Article
  19. Observational
  20. What's new in the prevention and treatment of cancer-associated thrombosis?Hematology. American Society of Hematology. Education Program · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

M CarrierDepartment of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON.
N BlaisDepartment of Medicine, Centre hospitalier de l'Université de Montréal, Montreal, QC.
M CrowtherDepartment of Medicine, McMaster University, Hamilton, ON.
P KavanDepartment of Oncology, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, QC.
G Le GalDepartment of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON.
O MoodleyDepartment of Hematology, Royal University Hospital, Saskatoon, SK.
S ShivakumarDepartment of Medicine, qeii Health Sciences Centre, Dalhousie University, Halifax, NS.
V TagalakisDepartment of Medicine, Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Montreal, QC.
C WuDepartment of Medicine, University of Alberta, Edmonton, AB.
A Y Y LeeDepartment of Medicine, University of British Columbia, BC Cancer, Vancouver, BC.
University of Ottawa · CACentre Hospitalier de l’Université de Montréal · CAHealth Sciences Centre · CAJewish General Hospital · CAMcGill University · CAMcMaster University · CARoyal University Hospital · CAUniversity of Alberta · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Management of anticoagulant therapy for the treatment of venous thromboembolism (vte) in cancer patients is complex because of an increased risk of recurrent vte and major bleeding complications in those patients relative to the general population. Subgroups of patients with cancer also show variation in their risk for recurrent vte and adverse bleeding events. Accordingly, a committee of 10 Canadian clinical experts developed the consensus risk- stratification treatment algorithm presented here to provide guidance on tailoring anticoagulant treatment choices for the acute and extended treatment of symptomatic and incidental vte, to prevent recurrent vte, and to minimize the bleeding risk in patients with cancer. During a 1-day live meeting, a systematic review of the literature was performed, and a draft treatment algorithm was developed. The treatment algorithm was refined through the use of a Web-based platform and a series of online teleconferences. Clinicians using this treatment algorithm should consider the bleeding risk, the type of cancer, and the potential for drug-drug interactions in addition to informed patient preference in determining the most appropriate treatment for patients with cancer-associated thrombosis. Anticoagulant therapy should be regularly reassessed as the patient's cancer status and management change over time.

Indexed as

AlgorithmsAnticoagulantsCanadaConsensusHumansNeoplasmsThrombosisAnticoagulantshemorrhageheparinKey Words Venous thromboembolismlow-molecular-weightvenous thrombosis

Identifiers

PMID30464682
PMCPMC6209545
OpenAlexW2899289768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.